AstraZeneca has announced the launch of Evinova, a new health-tech business focused on clinical-trial design and study delivery. The separate business will leverage the company’s knowledge and expertise in these areas to deliver solutions at scale to trial sponsors, clinical-research organizations, care teams, and patients. This includes improved data collection and machine-learning algorithms to support teams designing their studies.
The goal of Evinova is to reduce the time and cost of developing new medicines, bring care closer to home for patients, and reduce the burden on health systems. AstraZeneca has already established major collaborations with clinical-research organizations Parexel and Fortrea, which will enable Evinova’s digital-health solutions to be offered to their wide customer base.
AstraZeneca’s Chief Executive, Pascal Soriot, expressed optimism about the impact of Evinova, stating that the combination of scientific expertise and AI-enabled digital technologies has the potential to fundamentally improve patient care, drive healthcare transformation, and reduce carbon emissions.
The company has also highlighted the significant growth expected in the digital-health market, estimating it to be worth more than $900 billion by 2032. Research and development of digital health and care delivery with remote patient monitoring is projected to make up around 60% of the total market. This announcement represents AstraZeneca’s commitment to innovation and leveraging technology to enhance healthcare delivery.